Search

Paliperidone

Paliperidone was approved by the FDA for treatment of schizophrenia on December 20, 2006. … Paliperidone is also active as an antagonist at alpha 1 and alpha 2 adrenergic receptors and H1 histaminergic receptors, which may explain some of the other effects of the drug.

Levodopa

Once past the blood-brain barrier, levodopa is metabolized to dopamine and supplements the low endogenous levels of dopamine to treat symptoms of Parkinson's[Label]. … The first developed drug product that was approved by the FDA was a levodopa and carbidopa combined product called Sinemet that was approved on May 2, 1975[A177781,L6133].

Synthetic camphor

Olopatadine

An ophthalmic solution of olopatadine was approved by the FDA and European Union for the treatment of seasonal and perennial allergic conjunctivitis in 1996 and 2002, respectively. … It is a structural analog of [doxepin], which has a minimal anti-allergic activity.

Masitinib

It has been available in Europe since 2009, under the brand name Masivet. In the USA it is distributed under the name Kinavet and has been available for veterinaries since 2011.

Pancrelipase

[L2509] The pancrelipase mixture was developed by Ortho-McNeil-Janssen Pharmaceuticals, Inc and FDA approved on April 12, 2010.

Ceftizoxime

It has few side effects and is reported to be safe and effective in aged patients and in patients with hematologic disorders.

Ajmaline

It has also been used for many years as a drug to challenge the conduction system of the heart in cases of bundle branch block and syncope. … In these cases, abnormal prolongation of the HV interval has been taken as a proof for infrahisian conduction defects tributary for permanent pacemaker implantation.

Dequalinium

Due to its flexible structure, dequalinium was investigated to build drug and gene delivery systems. … [A249255] It is a quaternary ammonium compound,[L42190] as it consists of an amphipathic cation with two aminoquinaldinium rings at both ends of a long hydrophobic hydrocarbon chain.

Tideglusib

[A31601] Tideglusib is being developed by the Spanish pharmaceutic company Zeltia group and its current status is withdrawn for the treatment of Alzheimer's disease as of 2012.